<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323748</url>
  </required_header>
  <id_info>
    <org_study_id>14124</org_study_id>
    <nct_id>NCT04323748</nct_id>
  </id_info>
  <brief_title>Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura</brief_title>
  <acronym>NYMC207</acronym>
  <official_title>The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a dose dense administration of Rituximab in&#xD;
      newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate&#xD;
      following this treatment.&#xD;
&#xD;
      Correlative studies will be performed as outlined in the appendices.&#xD;
&#xD;
      Quality of Life will be measured using the KIT as outlined in the protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety events: Number of participants with treatment-related Grade III or higher adverse events as assessed by CTCAE v5.0.</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the occurrence of any Grade ≥ 3 non hematologic toxicity (per CTCAE v.5) which is possibly, probably, or definitely related to rituximab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>To quantify remission rates for high-risk patients with acute ITP treated with a dose dense administration of rituximab.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Immune Thrombocytopenic Purpura</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled will receive the dose dense administration of rituximab. Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituxan</intervention_name>
    <description>The dose dense administration of rituximab will consist of 5 doses total&#xD;
Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: Subjects must be ≥ 1 year and ≤ 21 years of age.&#xD;
&#xD;
          -  Diagnosis: Patients must have newly diagnosed ITP and a platelet count of ≤ 20 x 109&#xD;
             per Liter. Bone marrow aspirate and biopsy should be performed to rule out malignancy&#xD;
             in the bone marrow.&#xD;
&#xD;
          -  High-risk features : In addition, patients must have one of more of the following&#xD;
             high-risk criteria:&#xD;
&#xD;
               -  Age ≥ 10 years&#xD;
&#xD;
               -  Grade II-IV bleeding at diagnosis&#xD;
&#xD;
               -  ANA positivity&#xD;
&#xD;
               -  No history of preceding infection within 2 weeks prior to ITP diagnosis&#xD;
&#xD;
          -  Performance Status: Patients must have a performance status ≥ 50%. Use Karnofsky for&#xD;
             patients &gt; 16 years of age and Lansky for patients less than or equal to 16 years of&#xD;
             age. See Appendix I for performance score.&#xD;
&#xD;
          -  Prior Therapy&#xD;
&#xD;
               -  Patients may not have received any treatment for ITP prior to start of therapy.&#xD;
&#xD;
               -  Patients may not receive systemic steroids ≥ 0.5 mg/kg prednisone (or equivalent)&#xD;
                  within 2 weeks prior to diagnosis.&#xD;
&#xD;
          -  Concomitant Medications Restrictions:&#xD;
&#xD;
               -  Steroids are only warranted as premedication prior to rituximab.&#xD;
&#xD;
               -  Patients who receive thrombopoetic agonists, eltrombopag or romiplostim will be&#xD;
                  taken off protocol.&#xD;
&#xD;
          -  Organ Function Requirements&#xD;
&#xD;
               -  Adequate Renal Function Defined As: estimated CrCl &gt; 60 mL/min or &gt;30% of GFR for&#xD;
                  age based on the Schwartz formula&#xD;
&#xD;
               -  Adequate Liver Function Defined As: AST and/or ALT less than 5 times the upper&#xD;
                  limit of normal, and/or direct bilirubin less than the 2 times of the upper limit&#xD;
                  of normal&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with a history of Grade III-IV allergic reaction to rituximab&#xD;
&#xD;
          -  Patients with bone marrow neoplastic infiltration&#xD;
&#xD;
          -  Patients with a history of hepatitis B infection&#xD;
&#xD;
          -  Pregnancy and Breast Feeding&#xD;
&#xD;
               -  Female patients who are pregnant are ineligible (insert the reason: &quot;due to risks&#xD;
                  of fetal and teratogenic adverse events as seen in animal/human studies&quot; or&#xD;
                  &quot;since there is yet no available information regarding human fetal or teratogenic&#xD;
                  toxicities&quot;).&#xD;
&#xD;
               -  Lactating females are not eligible unless they have agreed not to breastfeed&#xD;
                  their infants.&#xD;
&#xD;
               -  Female patients of childbearing potential are not eligible unless a negative&#xD;
                  pregnancy test result has been obtained.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan Milner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Morris, RN</last_name>
    <phone>714-964-5359</phone>
    <email>erin_morris@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Harrison, MSN</last_name>
    <phone>617-285-7844</phone>
    <email>lauren_harrison@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Milner, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Mintzer, CRA</last_name>
      <email>emintzer2@nymc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

